The present disclosure relates to the methods and compositions for enhancing productivity or yield in fermentation. The methods and compositions provide culturing host cells at a high pH and compositions for culturing host cells at a high pH.
Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a detectable target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Provided herein are methods for a robust production of isoprenoids via one or more biosynthetic pathways. Also provided herein are nucleic acids, enzymes, expression vectors, and genetically modified host cells for carrying out the subject methods. Also provided herein are fermentation methods for high productivity of isoprenoids from genetically modified host cells.
C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
C12N 1/32 - Processes using, or culture media containing, lower alkanols, i.e. C1 to C6
The present disclosure relates to the production of organic compounds by host cell cultures, in particular, organic compounds which are inhibitory to host cells and/or are susceptible to chemical modification, including degradation and/or oxidation, in cell culture conditions. Improved systems and methods are herein disclosed for alleviating inhibition of host cells caused by product accumulation in the culture medium, thereby enhancing cell health and performance, including, for example, increased yield and productivity. Product recovery and purity are furthermore improved.
Provided herein are olefinic feedstocks derived from conjugated hydrocarbon terpenes (e.g., C10-C30 terpenes), methods for making the same, and methods for their use.
C07C 5/03 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by hydrogenation of non-aromatic carbon-to-carbon double bonds
C10L 1/04 - Liquid carbonaceous fuels essentially based on blends of hydrocarbons
Provided herein are cosmetic compositions for increasing the integrity of the skin or hair a subject or for reducing irritation of the skin of a subject and methods of using the cosmetic compositions. The cosmetic compositions contain a combination of a occlusive compound and an osmolyte compound. The occlusives of the combinations are squalane, hemisqualane, isosqualane, squalene, or isosqualene. The preferred osmolyte is ectoine. The cosmetics or pharmaceuticals may be used to increase the barrier of the skin or hair, increase the integrity of skin or hair, reduce inflammation of the skin, or prevent aging of the skin of a subject.
Provided herein are host cells capable of producing a human milk oligosaccharide (HMO), such as yeast cells that are deficient in expression or activity of an endogenous oxidoreductase. Also provided are fermentation compositions including the disclosed host cells, as well as related methods of producing and recovering HMOs generated by the host cells.
The compositions and methods of the disclosure can be used to purify a cannabinoid in a host cell, such as a yeast cell, genetically modified to express the enzymes of a cannabinoid biosynthetic pathway. Using the compositions and methods of the disclosure, a fermentation composition may be contacted with an enzymatic composition including a serine protease to purify a cannabinoid.
The present disclosure provides systems and methods for the production and recovery of volatile molecules, such as terpenes, and in particular, monoterpenes. By employing the systems and methods disclosed herein, volatile molecules may be recovered from the liquid contents of a bioreactor as well as the air space or headspace of the bioreactor, significantly improving overall recovery.
The present disclosure features compositions and methods for producing one or more cannabinoids, such as cannabidiolic acid (CBDa), in a host cell, such as a yeast cell, that is genetically modified to express the enzymes of a cannabinoid biosynthetic pathway. Using the compositions and methods of the present invention, the host cell may be genetically modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as an enzyme having CBDa synthase (CBDaS) activity.
The present disclosure features compositions and methods for producing one or more isoprenoid compounds, such as gamma-ambryl acetate (GAA), in a host cell, such as a yeast cell, that is genetically modified to express the enzymes of an isoprenoid biosynthetic pathway, such as a pathway for making GAA. Using the compositions and methods of the present invention, the host cell may be genetically modified to express one or more enzymes of an isoprenoid biosynthetic pathway, such as an enzyme capable of converting manooloxy to GAA. The host cell may be cultured in a medium, for example, in the presence of an agent that regulates expression of the one or more enzymes. The host cell may be incubated for a time sufficient to allow for production of an isoprenoid compound, such as GAA. The isoprenoid compound may then be separated from the host cell or from the medium.
N-HETEROCYCLYL SUBSTITUTED 2-CYANO-3-(NAPHTHALEN-2-YL)ACRYLAMIDE DERIVATIVES AS FLUOROPHORS FOR DETECTION OF AMYLOID AND AMYLOID-LIKE PROTEINS FOR DIAGNOSIS OF NEURODEGENERATIVE DISORDERS
Provided herein is the design and synthesis of novel molecular rotor fluorophores of formula I useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are the compounds for use in methods for diagnosis and treatment of diseases associated with an amyloid or amyloid like proteins, such as e.g. Alzheimer's disease or traumatic brain injury (TBI), Parkinson's disease, vascular dementia, amyotrophic lateral sclerosis, Down syndrome, traumatic brain injury, chronic traumatic encephalopathy, schizophrenia or depression. Exemplary compounds are e.g. N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives, such as e.g. (E)-2-cyano-N-(2-(2-hydroxy)ethoxy)ethyl)-3-(6-(pyrrolidin-1-yl)naphthalen-2-yl) acrylamide (example 1): Experimental data on in-vitro binding studies with amyloid beta is provided.
Provided herein is the design and synthesis of novel molecular rotor fluorophores of formula I useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are the compounds for use in methods for diagnosis and treatment of diseases associated with an amyloid or amyloid like proteins, such as e.g. Alzheimer's disease or traumatic brain injury (TBI), Parkinson's disease, vascular dementia, amyotrophic lateral sclerosis, Down syndrome, traumatic brain injury, chronic traumatic encephalopathy, schizophrenia or depression. Exemplary compounds are e.g. N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives, such as e.g. (E)-2-cyano-N-(2-(2-hydroxy)ethoxy)ethyl)-3-(6-(pyrrolidin-1-yl)naphthalen-2-yl) acrylamide (example 1): Experimental data on in-vitro binding studies with amyloid beta is provided.
C07D 203/10 - Radicals substituted by singly bound oxygen atoms
C07D 203/14 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
C07D 211/14 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
The present disclosure features compositions and methods for producing one or more isoprenoid compounds, such as E-copalol, in a host cell, such as a yeast cell, that is genetically modified to express the enzymes of an isoprenoid biosynthetic pathway, such as a pathway for making E-copalol. Using the compositions and methods of the present invention, the host cell may be genetically modified to express one or more enzymes of an isoprenoid biosynthetic pathway, such as a copalyl-diphosphate (CPP) pyrophosphatase. The host cell may then be cultured in a medium, for example, in the presence of an agent that regulates expression of the one or more enzymes. The host cell may further be incubated for a time sufficient to allow for production of an isoprenoid compound, such as E-copalol, by the host cell. The isoprenoid compound may then be separated from the host cell or from the medium.
The present invention provides compounds derived from farnesene and methods of producing the compounds from farnesene. In addition, compositions and methods of using the compositions as personal care products and other consumer products are provided, wherein the compositions comprise compounds derived from farnesene.
C07D 307/33 - Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
C07C 69/003 - Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
C07C 69/22 - Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
16.
COMPOSITIONS AND METHODS FOR IMPROVED PRODUCTION OF HUMAN MILK OLIGOSACCHARIDES
Provided herein are host cells capable of producing a human milk oligosaccharide (HMO) or HMO precursor, such as yeast cells that include one or more heterologous nucleic acids encoding one or more enzymes of an HMO biosynthetic pathway, such as a sialic acid synthase, a UDP-N-acetylglucosamine 2-epimerase, a β-galactoside-α-2,6-sialyltransferase, and/or a CMP-Neu5Ac synthetase. Also provided are fermentation compositions including the disclosed host cells, as well as related methods of producing and recovering HMOs or HMO precursors generated by the host cells.
Provided herein are recombinant host cells, compositions, and methods for the production of retinol, retinal, beta-carotene, lycopene, or phytoene (retinol or retinol precursor). The host cells are genetically modified to contain heterologous nucleic acids that express novel enzymes that enable the host cell to produce the retinol or retinol precursor from a carbon source such as sucrose. The host cells, compositions, and methods disclosed herein provide an efficient route for the heterologous production of retinol, retinal, beta-carotene, lycopene, or phytoene.
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
Provided herein are recombinant host cells, compositions, and methods for the production of the sesquiterpenoids: alpha-humulene, beta-caryophyllene, valencene, delta-cadinene, delta-guaiene, germacrene A, germacrene D, beta- cubebene, valerena-4,7(11)-diene, nerolidol, and bisabolol. The host cells are genetically modified to contain heterologous nucleic acids that express novel enzymes that enable the host cell to produce the sesquiterpenoids from a carbon source such as sucrose. The host cells, compositions, and methods disclosed herein provide an efficient route for the heterologous production of alpha-humulene, beta-caryophyllene, valencene, delta-cadinene, delta-guaiene, germacrene A, germacrene D, beta-cubebene, valerena-4,7(11)-diene, nerolidol, or bisabolol.
Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.
C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07C 255/42 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
C07C 255/58 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
C07C 255/59 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
C07C 311/35 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
C07D 211/06 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
C07D 307/52 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 333/22 - Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 407/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
Provided herein methods of producing and isolating a cannabinoid from a fermentation composition including are host cells capable of producing a cannabinoid such by combining a mixture including a cannabigerolic acid with a cannabichromenic acid (CBCa) synthase, optionally in an oil mixture. Also provided herein are CBCa synthases having improved activity in comparison to the wild-type enzyme.
Provided herein are hair care compositions containing a sugar cane derived alkanes or squalane and which are generally free from silicones. The hair care compositions provided have beneficial properties including UV and thermal protection as well as restorative and protective properties. Also provided are methods of restoring and protecting hair from damage caused by frequent styling.
Provided herein are genetically modified host cells. compositions. and methods for improved production of vanillin and/or glucovanillin. The host cells. compositions. and methods described herein provide an efficient route for the heterologous production of vanillin and/or glucovanillin and any compound that can be synthesized or biosynthesized from either or both.
Provided herein are methods and compositions for determining whether a patient suffers from systemic amyloidosis, comprising detecting the presence of a misfolded or aggregated protein in a tissue of the patient, wherein the detecting comprises contacting the misfolded or aggregated transthyretin protein with a compound described herein. In some embodiments, the misfolded or aggregated protein is transthyretin.
The disclosure provides cosmetic compositions including cannabigerol (CBG), as well as methods of using the same for reducing skin redness, improving skin barrier functionality, brightening the skin of a subject, and enhancing the outward appearance of the skin of a subject (e.g., a male or female human subject).
Provided herein are methods of isolating a retinoid that includes: providing a fermentation broth comprising the retinoid and an overlay; performing a liquid-solid and liquid-liquid separation on the fermentation broth to produce a crude oil and a waste heavy phase; mixing the crude oil with a solvent extraction system to extract the retinoid from the crude oil; and stripping the solvent extraction system from the extracted retinoid to thereby isolate the retinoid. Also provided herein are methods of isolating a retinoid from a composition including the retinoid and farnesol that include: providing a composition including the retinoid and farnesol; feeding the composition into a chromatography system; and collecting the retinoid, thereby isolating the retinoid.
C07C 403/08 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by hydroxy groups
28.
COMPOSITIONS AND METHODS FOR PRODUCTION OF MYRCENE
Provided herein are compositions and methods for producing myrcene by culturing genetically modified microbial host cells that express a myrcene synthase and optionally a geranyl pyroplosphate synthase. Also provided herein are isolated nucleic acid molecules that encode myrcene synthase variants derived from the Ocimum species myrcene synthase, which comprise one or more amino acid substitutions that improve in vivo performance of myrcene synthase in genetically modified microbial host cells. Also provided herein are isolated myrcene synthase variants that exhibit an improved activity for converting geranyl diphosphate into myrcene.
Provided herein are variant β-1,3-N-acetylglucosaminyltransferase polypeptides capable of producing lacto-n-neotetraose, yeast cells capable of producing one or more human milk oligosaccharides, and methods of making such cells. Also, provided are fermentation compositions including the disclosed genetically modified yeast cells, and related methods of producing and recovering HMOs generated by the yeast cells.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
C07C 5/03 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by hydrogenation of non-aromatic carbon-to-carbon double bonds
C10L 1/04 - Liquid carbonaceous fuels essentially based on blends of hydrocarbons
Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a detectable target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Provided herein are methods for a robust production of isoprenoids via one or more biosynthetic pathways. Also provided herein are nucleic acids, enzymes, expression vectors, and genetically modified host cells for carrying out the subject methods. Also provided herein are fermentation methods for high productivity of isoprenoids from genetically modified host cells.
C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes
C12N 1/32 - Processes using, or culture media containing, lower alkanols, i.e. C1 to C6
Provided herein are fermentation compositions and methods for improved production of vanillin and/or glucovanillin. The compositions and methods described herein provide efficient routes for the production of vanillin and/or glucovanillin and any compound that can be synthesized or biosynthesized from either or both.
The present disclosure provides compositions and methods for producing high-purity squalene from a squalene source, for example from host cells, such as yeast cells that are capable of synthesizing squalene. Further provided herein are compositions containing high-purity squalene, as well as methods of using the same in pharmaceutical formulations, such as in adjuvant formulations for use in vaccines.
C07C 7/10 - Purification, separation or stabilisation of hydrocarbonsUse of additives by extraction, i.e. purification or separation of liquid hydrocarbons with the aid of liquids
The present disclosure relates to the methods and compositions for enhancing productivity or yield in fermentation. The methods include culturing host cells at a high pH to increase oxygen uptake as well as a higher yield and productivity of the compositions produced using the methods.
The present disclosure provides compositions and methods for producing a cell culture product in a cell culture composition, particularly for cell culture product s that impair the growth and/or function of the host cells in which they are biosynthesized, such as isoprenoids or terpenes.
C07C 7/10 - Purification, separation or stabilisation of hydrocarbonsUse of additives by extraction, i.e. purification or separation of liquid hydrocarbons with the aid of liquids
C12P 1/02 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using fungi
C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
C12M 1/00 - Apparatus for enzymology or microbiology
Provided herein are genetically modified yeast cells capable of producing one or more human milk oligosaccharides (HMOs) and methods of making such cells. The yeast cells are engineered to comprise a heterologous nucleic acid encoding a variant ABC transporter protein YOR1 from Saccharomyces cerevisiae with improved 2'-fucosyllactose export activity and one or more heterologous nucleic acids that encode enzymes of a HMO biosynthetic pathway. Also provided are fermentation compositions including the disclosed genetically modified yeast cells, and related methods of producing and recovering HMOs generated by the yeast cells.
C12P 19/00 - Preparation of compounds containing saccharide radicals
C12N 15/01 - Preparation of mutants without inserting foreign genetic material thereinScreening processes therefor
C07K 14/395 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts from Saccharomyces
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
38.
COMPOSITIONS AND METHODS FOR IMPROVED PRODUCTION OF STEVIOL GLYCOSIDES
Provided herein are variant uridine-5'-diphosphate glycosyltransferase polypeptides capable of producing steviol glycosides, yeast cells capable of producing steviol glycosides, and methods of making such cells. Also provided are fermentation compositions including the disclosed host cells, and related methods of producing and recovering steviol glycosides generated by the yeast cells.
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
39.
Compounds, compositions, and methods for recovering water-immiscible compounds from microbial biomass
The disclosure provides compounds useful as adjuvants in vaccines, as well as methods of synthesizing such compounds and methods of using such compounds in the formulation of a vaccine. The disclosure also features methods of administering such vaccines to a subject (e.g., a mammalian subject, such as a human) in order to treat or prevent one or more diseases, such as a disease caused by a viral or bacterial infection.
C07C 43/215 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
C07C 49/258 - Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing —CHO groups
The compositions and methods of the disclosure can be used to produce a cannabinoid in a host cell, such as a yeast cell. For example, the disclosure features host cells (e.g., yeast cells) modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as an acyl activating enzyme (AAE), a tetraketide synthase (TKS), a cannabigerolic acid synthase (CBGaS), and/or an olivetolic acid cyclase (OAC).
Provided herein are sunscreen formulations containing a metal oxide sunscreen, squalane, and an antioxidant. The sunscreen formulations provided have increased SPF per unit mass of the metal oxide compared to sunscreen formulations that contain metal oxide without the addition of squalane and antioxidant. Also provided are methods of preventing UV damages to skin involving the application of the sunscreen formulation.
A method includes causing a graphical user interface to be output to a display. The method also includes detecting a triggering of a purchase icon by a first user and causing a transaction to occur. The transaction is a commitment by the first user to spend a minimum amount of currency on one or more products or services being offered by a presenter. The method further includes detecting a triggering of a sharing icon to cause information to be shared with a second user. The information includes one or more selectable links configured to facilitate one or more of accessing of a video or purchasing the one or more products or services being offered. The method additionally includes monitoring data indicative of how the second user interacts with the information and linking the data indicative of how the second user interacts with the information to the first user.
G06F 3/04817 - Interaction techniques based on graphical user interfaces [GUI] based on specific properties of the displayed interaction object or a metaphor-based environment, e.g. interaction with desktop elements like windows or icons, or assisted by a cursor's changing behaviour or appearance using icons
G06Q 30/0207 - Discounts or incentives, e.g. coupons or rebates
G06Q 50/00 - Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
44.
COMPOSITIONS AND METHODS FOR IMPROVED PRODUCTION OF HUMAN MILK OLIGOSACCHARIDES
Provided herein are host cells capable of producing a human milk oligosaccharide (HMO), such as yeast cells that include one or more heterologous nucleic acids encoding one or more enzymes of the HMO biosynthetic pathway, such as a fucosyltransferase, GDP-mannose dehydratase, lactose permease, and/or fucose synthase. Also provided are fermentation compositions including the disclosed host cells, as well as related methods of producing and recovering HMOs generated by the host cells.
Provided herein are sunscreen formulations containing a metal oxide sunscreen, squalane, and an antioxidant. The sunscreen formulations provided have increased SPF per unit mass of the metal oxide compared to sunscreen formulations that contain metal oxide without the addition of squalane and antioxidant. Also provided are methods of preventing UV damages to skin involving the application of the sunscreen formulation.
Provided herein are host cells capable of producing a human milk oligosaccharide (HMO), such as yeast cells that are deficient in expression or activity of an endogenous oxidoreductase. Also provided are fermentation compositions including the disclosed host cells, as well as related methods of producing and recovering HMOs generated by the host cells.
Provided herein antiperspirant composition formulations that contain hemisqualane and lack organosilicon compounds. The hemisqualane provides the carrier and emollient activities that are typically supplied by an organosilicon compound. The antiperspirant formulations provided herein have a benefit of not releasing organosilicon compounds into the environment during and after their use.
Provided herein are genetically modified host cells, compositions, and methods for improved production of artemisinic acid. The host cells are genetically modified to contain a heterologous nucleic acid that expresses novel and optimized variants of amorpha-4,11-diene 12-monooxygenase. Also provided herein are methods for screening for variants of cytochrome p450 enzymes that have increased enzymatic activity relative to a parental control enzyme.
N-HETEROCYCLYL SUBSTITUTED 2-CYANO-3-(NAPHTHALEN-2-YL)ACRYLAMIDE DERIVATIVES AS FLUOROPHORS FOR DETECTION OF AMYLOID AND AMYLOID-LIKE PROTEINS FOR DIAGNOSIS OF NEURODEGENERATIVE DISORDERS
Provided herein is the design and synthesis of novel molecular rotor fluorophores of formula I useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are the compounds for use in methods for diagnosis and treatment of diseases associated with an amyloid or amyloid like proteins, such as e.g. Alzheimer's disease or traumatic brain injury (TBI), Parkinson's disease, vascular dementia, amyotrophic lateral sclerosis, Down syndrome, traumatic brain injury, chronic traumatic encephalopathy, schizophrenia or depression. Exemplary compounds are e.g. N-heterocyclyl substituted 2-cyano-3- (naphthalen-2-yl)acrylamide derivatives, such as e.g. (E)-2-cyano- N-(2-(2-hydroxy)ethoxy)ethyl)-3-(6-(pyrrolidin-1-yl)naphthalen-2-yl) acrylamide (example 1): Experimental data on in-vitro binding studies with amyloid beta is provided.
A61K 31/396 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07D 295/14 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
The present disclosure features compositions and methods for producing one or more cannabinoids, such as cannabidiolic acid (CBDa), in a host cell, such as a yeast cell, that is genetically modified to express the enzymes of a cannabinoid biosynthetic pathway. Using the compositions and methods of the present invention, the host cell may be genetically modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as an enzyme having CBDa synthase (CBDaS) activity.
C12N 15/52 - Genes encoding for enzymes or proenzymes
C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
The present disclosure features compositions and methods for producing one or more cannabinoids, such as cannabidiolic acid (CBDa) or cannabidiol (CBD), in a host cell, such as a yeast cell, that is genetically modified to express the enzymes of a cannabinoid biosynthetic pathway. Using the compositions and methods of the present invention, the host cell may be genetically modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as CBDaS. The host cell may be cultured in the medium in the presence of a first cannabinoid, for example CBGa, and incubated for a time sufficient to allow for bioconversion of the first cannabinoid to a second cannabinoid, for example CBDa, by the host cell.
The present disclosure features compositions and methods for producing one or more isoprenoid compounds, such as gamma-ambryl acetate (GAA), in a host cell, such as a yeast cell, that is genetically modified to express the enzymes of an isoprenoid biosynthetic pathway, such as a pathway for making GAA. Using the compositions and methods of the present invention, the host cell may be genetically modified to express one or more enzymes of an isoprenoid biosynthetic pathway, such as an enzyme capable of converting manooloxy to GAA. The host cell may be cultured in a medium, for example, in the presence of an agent that regulates expression of the one or more enzymes. The host cell may be incubated for a time sufficient to allow for production of an isoprenoid compound, such as GAA. The isoprenoid compound may then be separated from the host cell or from the medium.
The present disclosure features compositions and methods for producing one or more isoprenoid compounds, such as E-copalol, in a host cell, such as a yeast cell, that is genetically modified to express the enzymes of an isoprenoid biosynthetic pathway, such as a pathway for making E-copalol. Using the compositions and methods of the present invention, the host cell may be genetically modified to express one or more enzymes of an isoprenoid biosynthetic pathway, such as a copalyl-diphosphate (CPP) pyrophosphatase. The host cell may then be cultured in a medium, for example, in the presence of an agent that regulates expression of the one or more enzymes. The host cell may further be incubated for a time sufficient to allow for production of an isoprenoid compound, such as E-copalol, by the host cell. The isoprenoid compound may then be separated from the host cell or from the medium.
The compositions and methods of the disclosure can be used to purify a cannabinoid in a host cell, such as a yeast cell, genetically modified to express the enzymes of a cannabinoid biosynthetic pathway. Using the compositions and methods of the disclosure, a fermentation composition may be contacted with an enzymatic composition including a serine protease to purify a cannabinoid.
The present disclosure features compositions and methods for producing one or more cannabinoids in a host cell that is genetically modified to express the enzymes of a cannabinoid biosynthetic pathway. Using the compositions and methods of the disclosure, a cannabinoid-producing host cell may be contacted with an oil so as to enhance the recovery of the cannabinoid from the host cell.
Provided herein are methods and compositions for determining whether a patient suffers from a neurological disease or disorder is provided, comprising detecting the presence of a phosphorylated tau protein in a tissue of the patient, wherein the detecting comprises contacting the phosphorylated tau protein with a compound described herein.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
57.
COMPOSITIONS AND METHODS FOR DELIVERING CANNABINOIDS TO SKIN
Provided herein are compositions for delivering one or more cannabinoids to the skin of a subject and methods of using the compositions to deliver the one or more cannabinoids to the skin of a subject. The compositions contain a carrier that facilitates the delivery and permeation of cannabinoids to and through the skin. The carriers of the compositions contain squalane or mixtures of squalane and hemisqualane. The compositions described herein may serve as the base for the preparation of various cosmetics or various pharmaceuticals. The cosmetics or pharmaceuticals may be used to reduce inflammation, control pain, or prevent aging of the skin of a subject.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.
Provided herein are compositions and methods for uncoupling the yield and productivity of an isoprenoid compound produced in a host cell. In some embodiments, the yield and productivity are uncoupled by genetically modifying the host cell to reduce flux through the citric acid cycle (TCA). In other embodiments, the yield and productivity are uncoupled by reducing the levels of ATP in the host cell.
Provided herein are genetically modified yeast cells capable of producing one or more human milk oligosaccharides (HMOs) and methods of making such cells. The yeast cells are engineered to comprise a heterologous nucleic acid encoding a transporter protein and one or more heterologous nucleic acids that encode enzymes of a HMO biosynthetic pathway. Also provided are fermentation compositions including the disclosed genetically modified yeast cells, and related methods of producing and recovering HMOs generated by the yeast cells.
Provided herein are genetically modified host cells, compositions, and methods for improved production of vanillin and/or glucovanillin. The host cells, compositions, and methods described herein provide an efficient route for the heterologous production of vanillin and/or glucovanillin and any compound that can be synthesized or biosynthesized from either or both.
Provided herein are methods and compositions for determining whether a patient suffers from systemic amyloidosis, comprising detecting the presence of a misfolded or aggregated protein in a tissue of the patient, wherein the detecting comprises contacting the misfolded or aggregated transthyretin protein with a compound described herein. In some embodiments, the misfolded or aggregated protein is transthyretin.
Provided herein are genetically modified host cells, compositions, and methods for improved production of vanillin and/or glucovanillin. The host cells, compositions, and methods described herein provide an efficient route for the heterologous production of vanillin and/or glucovanillin and any compound that can be synthesized or biosynthesized from either or both.
Provided herein are genetically modified host cells, compositions, and methods for improved production of steviol glycosides. The host cells are genetically modified to contain a heterologous nucleic acid that expresses novel and optimized variants of Ro.KAH. The host cell further contains one or more heterologous nucleotide sequence encoding further enzymes of a pathway capable of producing one or more steviol glycosides in the host cell. The host cells, compositions, and methods described herein provide an efficient route for the heterologous production of steviol glycosides including rebaudioside A, rebaudioside D, and rebaudioside M.
C12P 19/56 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
66.
Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
Provided herein are compositions and methods of integrating one or more exogenous donor nucleic acids into one or more exogenous landing pads engineered into a host cell's genome. In certain embodiments, the exogenous landing pads and exogenous donor nucleic acids comprise standardized, compatible homology regions so that exogenous donor nucleic acids can integrate into any of the landing pads, independent of the genomic sequences surrounding the landing pads. In certain embodiments, the methods comprise contacting the host cell comprising landing pads with one or more exogenous donor nucleic acids, and a nuclease capable of causing a double-strand break within the landing pads, and recovering a host cell comprising one or more exogenous donor nucleic acids integrated in any of the landing pads.
The disclosure provides cosmetic compositions including cannabigerol (CBG), as well as methods of using the same for reducing skin redness, improving skin barrier functionality, brightening the skin of a subject, and enhancing the outward appearance of the skin of a subject (e.g., a male or female human subject).
Provided herein are variant β-1,3-N-acetylglucosaminyltransferase polypeptides capable of producing lacto-n-neotetraose, yeast cells capable of producing one or more human milk oligosaccharides, and methods of making such cells. Also, provided are fermentation compositions including the disclosed genetically modified yeast cells, and related methods of producing and recovering HMOs generated by the yeast cells.
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
C12N 15/67 - General methods for enhancing the expression
C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
C12N 15/70 - Vectors or expression systems specially adapted for E. coli
C07C 5/03 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by hydrogenation of non-aromatic carbon-to-carbon double bonds
Provide are modified host cells that are engineered to decrese expression of a product to undetectable levels in the presence of an exogenous agent, and increase expression of the product in the presence of another exogenous agent. The modified yeast strainshost cells do not express detectable levels of a precursor or substrate used to make the product. The product can be a cannabinoid or precursor thereof, and the substrate can be hexanoate. Also provided are methods for making a product using the modified host cells. The modified host cell can be a yeast strain, such as S. cerevisiae.
Provided herein are genetically modified host cells, compositions, and methods for improved production of steviol glycosides. In some embodiments, the host cell is genetically modified to comprise a heterologous nucleic acid expression cassette that expresses an ABC-transporter capable of transporting steviol glycosides to the extracellular space or to the luminal space of an intracellular organelle. In some embodiments, the host cell further comprises one or more heterologous nucleotide sequence encoding further enzymes of a pathway capable of producing one or more steviol glycosides in the host cell. The host cells, compositions, and methods described herein provide an efficient route for the heterologous production of steviol glycosides, including but not limited to, rebaudioside D and rebaudioside M.
C12P 19/56 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
Provided herein are fermentation compositions and methods for improved production of vanillin and/or glucovanillin in the presence of para-aminobenzoic acid (PABA, 4-aminobenzoic acid). The compositions and methods described herein provide efficient routes for the production of vanillin and/or glucovanillin and any compound that can be synthesized or biosynthesized from either or both.
Provided herein are fermentation compositions and methods for improved production of vanillin and/or glucovanillin in the presence of para-aminobenzoic acid (PABA, 4-aminobenzoic acid). The compositions and methods described herein provide efficient routes for the production of vanillin and/or glucovanillin and any compound that can be synthesized or biosynthesized from either or both.
The compositions and methods of the disclosure can be used to produce a cannabinoid in a host cell, such as a yeast cell. For example, the disclosure features host cells (e.g., yeast cells) modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as an acyl activating enzyme (AAE), a tetraketide synthase (TKS), a cannabigerolic acid synthase (CBGaS), and/or an olivetolic acid cyclase (OAC).
The compositions and methods of the disclosure can be used to produce a cannabinoid in a host cell, such as a yeast cell. For example, the disclosure features host cells (e.g., yeast cells) modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as an acyl activating enzyme (AAE), a tetraketide synthase (TKS), a cannabigerolic acid synthase (CBGaS), and/or an olivetolic acid cyclase (OAC).
Portable fluid dispensing apparatuses are disclosed. In some embodiments, the apparatus includes an upper assembly and a lower assembly. The lower assembly includes a base shell and a lid removably coupled to the base shell. The upper assembly includes an upper shell attached to the lid and having a first aperture. The upper assembly additionally includes a fluid dispenser attached to a neck portion of the lid and received. The fluid dispenser includes an actuator nozzle, a first tube received in a first internal compartment of the base shell, a pump disposed between the nozzle and the first tube. The upper assembly further includes a pump control member having a second tube connected to the nozzle. The pump control member is sized to allow movement of the pump control member and the nozzle toward the pump to activate the pump and dispense fluid stored in the first internal compartment.
The disclosure provides compounds useful as adjuvants in vaccines, as well as methods of synthesizing such compounds and methods of using such compounds in the formulation of a vaccine. The disclosure also features methods of administering such vaccines to a subject (e.g., a mammalian subject, such as a human) in order to treat or prevent one or more diseases, such as a disease caused by a viral or bacterial infection.
The disclosure provides compounds useful as adjuvants in vaccines, as well as methods of synthesizing such compounds and methods of using such compounds in the formulation of a vaccine. The disclosure also features methods of administering such vaccines to a subject (e.g., a mammalian subject, such as a human) in order to treat or prevent one or more diseases, such as a disease caused by a viral or bacterial infection.
Ocimum species myrcene synthase, which comprise one or more amino acid substitutions that improve in vivo performance of myrcene synthase in genetically modified microbial host cells. Also provided herein are isolated myrcene synthase variants that exhibit an improved activity for converting geranyl diphosphate into myrcene.
Provided herein are sunscreen formulations containing a metal oxide sunscreen, squalane, and an antioxidant. The sunscreen formulations provided have increased SPF per unit mass of the metal oxide compared to sunscreen formulations that contain metal oxide without the addition of squalane and antioxidant. Also provided are methods of preventing UV damages to skin involving the application of the sunscreen formulation.
Provided herein are sunscreen formulations containing a metal oxide sunscreen, squalane, and an antioxidant. The sunscreen formulations provided have increased SPF per unit mass of the metal oxide compared to sunscreen formulations that contain metal oxide without the addition of squalane and antioxidant. Also provided are methods of preventing UV damages to skin involving the application of the sunscreen formulation.
Provided herein are compounds, methods and compositions for determining whether a patient has a neurological disease or disorder is provided, comprising detecting the presence of a detectable target protein, or an accumulated mass thereof, for example, amyloid beta protein or phosphorylated tau protein, or an accumulated mass thereof, in a tissue or a sample of the patient. The detecting may comprise contacting the target protein with a compound described herein.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
84.
Stevia rebaudiana kaurenoic acid hydroxylase variants for high efficiency production of rebaudiosides
Stevia rebaudiana kaurenoic acid hydroxylase. In some embodiments, the host cell further comprises one or more heterologous nucleotide sequence encoding further enzymes of a pathway capable of producing one or more steviol glycosides in the host cell. The compositions and methods described herein provide an efficient route for the heterologous production of steviol glycosides, including but not limited to, rebaudioside D and rebaudioside M.
C12P 19/56 - Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins.
C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 211/06 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 295/04 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
C07D 307/52 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
C07D 333/22 - Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/10 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 407/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07C 255/42 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
C07C 255/58 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
C07C 255/59 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
C07C 311/35 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
C07C 255/43 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
Provided herein are compositions for delivering one or more cannabinoids to the skin of a subject and methods of using the compositions to deliver the one or more cannabinoids to the skin of a subject. The compositions contain a carrier that facilitates the delivery and permeation of cannabinoids to and through the skin. The carriers of the compositions contain squalane or mixtures of squalane and hemisqualane. The compositions described herein may serve as the base for the preparation of various cosmetics or various pharmaceuticals. The cosmetics or pharmaceuticals may be used to reduce inflammation, control pain, or prevent aging of the skin of a subject.
Provided herein are high potency sweeteners containing at least 95% rebaudioside M generated from Saccharomyces cerevisiae strains engineered to produce high purity rebaudioside M when fermented with sugar cane syrup. In addition, provided are methods of purifying the high potency sweeteners from cleared fermentation broths. Also provided are sugar substitutes containing the high potency sweeteners and methods of making same.
Provided herein are high potency sweeteners containing at least 95% rebaudioside M generated from Saccharomyces cerevisiae strains engineered to produce high purity rebaudioside M when fermented with sugar cane syrup. In addition, provided are methods of purifying the high potency sweeteners from cleared fermentation broths. Also provided are sugar substitutes containing the high potency sweeteners and methods of making same.
Provided herein are sunscreen formulations containing a metal oxide sunscreen, squalane, and an antioxidant. The sunscreen formulations provided have increased SPF per unit mass of the metal oxide compared to sunscreen formulations that contain metal oxide without the addition of squalane and antioxidant. Also provided are methods of preventing UV damages to skin involving the application of the sunscreen formulation.
Provided herein are sunscreen formulations containing a metal oxide sunscreen, squalane, and an antioxidant. The sunscreen formulations provided have increased SPF per unit mass of the metal oxide compared to sunscreen formulations that contain metal oxide without the addition of squalane and antioxidant. Also provided are methods of preventing UV damages to skin involving the application of the sunscreen formulation.
Provided herein are genetically modified host cells, compositions, and methods for improved production of artemisinic acid. The host cells are genetically modified to contain a heterologous nucleic acid that expresses novel and optimized variants of amorpha-4,11-diene 12-monooxygenase. Also provided herein are methods for screening for variants of cytochrome p450 enzymes that have increased enzymatic activity relative to a parental control enzyme.
The present disclosure relates to the use of a maltose dependent degron to control stability of a protein of interest fused thereto at the post-translational level. The present disclosure also relates to the use of a maltose dependent degron in combination with a maltose-responsive promoter to control gene expression at the transcriptional level and to control protein stability at the post-translational level. The present disclosure also relates to the use of a stabilization construct that couples expression of a cell-growth-affecting protein with the production of non-catabolic compounds. The present disclosure further relates to the use of a synthetic maltose-responsive promoter. The present disclosure further provides compositions and methods for using a maltose dependent degron, a maltose-responsive promoter, and a stabilization construct, either alone or in various combinations, for the production of non-catabolic compounds in genetically modified host cells.
C07K 14/395 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts from Saccharomyces
C12P 19/62 - Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
Provided herein are genetically modified host cells, compositions, and methods for improved production of artemisinic acid. The host cells are genetically modified to contain a heterologous nucleic acid that expresses novel and optimized variants of amorpha-4,11-diene 12-monooxygenase. Also provided herein are methods for screening for variants of cytochrome p450 enzymes that have increased enzymatic activity relative to a parental control enzyme.
A method for recovering one or more water immiscible compounds comprising acidifying and disrupting the microbial biomass; heating the acidified, disrupted microbial biomass to form a heated, acidified disrupted microbial biomass; and contacting the heated, acidified, disrupted microbial biomass with a disulfonated surfactant in an amount sufficient to release at least 30% of the one or more water immiscible compounds from the microbial biomass.
09 - Scientific and electric apparatus and instruments
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable computer software for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events by talent agencies; Downloadable computer application software for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events by talent agencies; downloadable computer software platform for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events by talent agencies; downloadable computer software for creating and organizing marketing materials; downloadable software for creating and organizing marketing materials; downloadable computer software for transmission of digital marketing materials; downloadable software for transmission of digital marketing materials; downloadable computer software for creating searchable databases of information and data; downloadable computer software for managing and analyzing marketing lead generation data; downloadable software for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable computer databases in the field of influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable electronic databases in the field of influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; computer software for database management; electronic databases in the field of influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events recorded on computer media; downloadable computer software for application and database integration; downloadable computer programs for accessing, browsing and searching online databases; downloadable computer software for creating searchable databases of information and data; downloadable software for data bank management; downloadable computer software for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable computer software platform for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable Software for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable computer software platforms for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable computer software platforms for collaborating on shared documents; downloadable application Programming interface (API) software; network servers for cloud-computing applications; downloadable Cloud computing software for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable computer application software used in cloud computing to influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable operating software and platforms used for digital telephone signal transmission; downloadable computer software platforms for accessing social networking websites; downloadable and recorded computer software platforms for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable communication software for provided access to the internet; downloadable telecommunications software for transmitting electronic messages; downloadable communications software for use in accessing data stored in the cloud; downloadable mobile application software for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable software drivers for electronic devices that allow computer hardware and electronic devices to communicate with each other; downloadable graphical user interface software; download software for managing networked computer systems; downloadable communications software for digital signal processing; downloadable communication, networking and social networking software for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable community software for use in content management on websites; blank data cartridges; wireless transmitters for telecommunications signals; downloadable software for use in transferring and tracking data over data networks; downloadable file sharing software; downloadable computer software and hardware apparatus for downloading, transmitting, receiving, providing, publishing, extracting, encoding, decoding, reading, storing and organizing audiovisual, videographic and written data; downloadable computer software for gathering, processing, monitoring, analyzing, managing and reporting information; downloadable computer software for gathering, processing, monitoring, analyzing, managing and reporting information concerning usage and performance of software, applications, websites, virtual worlds and audio visual content; downloadable computer software for gathering, processing, analyzing, managing and reporting information concerning online, internet and web site activity; downloadable computer software for designing, developing, modifying and improving computer software, applications, websites and audio visual content; pre-recorded electronic, magnetic and optical data carriers, namely, CDs and DVDs featuring talent agency services; downloadable electronic publications in the nature of magazines in the field of software via online databases, internet, websites and computer networks; electronic notice boards; downloadable mobile applications for talent agency services; downloadable software in the nature of a mobile application for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; downloadable computer platform software for accessing social networking websites; downloadable computer software for collecting, organizing, book marking, transmission, storage and sharing of data and information; downloadable digital audio files featuring talent agency services; blank magnetic data carriers, recordable discs, compact discs, DVDs, and USB flash drives Talent agency services, namely, business management of performing artists; business management of performing artists; Business management of musical performers; employment services in the nature of talent casting of performing artists in the fields of music, video and films; Negotiation of commercial transactions for performing artists; Employment recruiting in the nature of booking jobs for performing artists; Advertising and marketing; business administration relating to marketing; Advertising agencies; Advertising agency services; Advertising analysis; Advertising and advertisement services; Advertising and marketing consultancy; Advertising and marketing services provided by means of indirect methods of marketing communications, namely, social media, blogging, and other forms of passive, sharable or viral communications channels; Advertising and promotion services; Advertising and promotion services and related consulting; Advertising and publicity; Advertising, namely, promotion of products and services of third parties through sponsoring arrangements and license agreements; Advisory services for business management; Advisory services relating to advertising; Analysis relating to marketing; blogger outreach services, namely, promoting goods and services of others via online blogs; Business administration consultancy; business administration for others; Business administration services for processing sales made on the internet; Business administration services for the processing of sales made on a global computer network; Business administration services for the processing of sales made on the Internet; Business advice; Business advice relating to advertising; Business advice relating to marketing; Developing promotional campaigns for business; Development and implementation of marketing strategies for others; Development of advertising concepts; Digital advertising services; Digital marketing; Database management and compilation of information on computerised databases; Business management assistance; business management assistance for promoting the goods and services of others; assistance with business management and planning; business management assistance services; Managing and operating businesses for others in the field of influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; Management of computer databases; business management of performing artists Development of computer software, computer software applications, and computer platform software for use in the field of talent agency operation; Platform as a Service (PaaS) featuring computer software platforms for influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; Platform as a Service (PaaS) featuring software platforms for developing marketing campaigns; Software as a service (SaaS) featuring software for organizing marketing data; Software as a service (SaaS) featuring software for managing and analyzing marketing lead generation data; Database design and development; Development of Software for the analysis of business data; Development of Software for the analysis of marketing data; Development of Software platforms for the analysis of business data; Development of Software platforms for the analysis of marketing data; Development of Cloud computing software for the analysis of business data; Development of Cloud computing software for the analysis of marketing data; Development of Software for the modelling of business data; Development of Software for the modelling of marketing data; Development of computer Platform Software for the modelling of business data; Development of computer Platform Software for the modelling of marketing data; Development of Cloud computing software for the modelling of business data; Development of Cloud computing software for the modelling of marketing data; Maintenance of online databases for others; Reconstitution of databases; computer services, namely, hosting computer databases of others on a computer network; Consulting services in the field of software as a service (SaaS) for lead generation and lead management; Software as a service (SaaS) services featuring software for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; Consulting services in the field of software as a service (SaaS); Software development services; software design and development; Software engineering services; software creation; Software customisation services; Computer software integration; Software design for others; Software as a service services featuring software for influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; Computer software advisory services; Computer software consultancy services; Computer software design and development; Development of computer platforms; Hosting of digital content and websites of others on the Internet; Programming of software for Internet platforms; Programming of software for information platforms on the Internet; designing computing platform software for third parties; Software as a service (SaaS) services featuring computer software platforms for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; Computer programming services; Computer software development consisting of the design, maintenance, programming, engineering, research and computer code writing services; advisory and consultancy services relating to computer software and computer software development, design, maintenance, consultancy, programming, engineering, research and computer code writing; Technical data analysis services in the field of software development and design; design and development of computer hardware and software; electronic data storage; Computer services, namely, cloud hosting provider services; application service provider services featuring software application for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; providing temporary use of online non-downloadable software for use in influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; computer consultation; consulting in the field of information technology; computer consultation in the field of cloud computing; hosting online web facilities for others for influencer marketing, influencer strategy, content production, campaign amplification, social media campaigns and branded events; hosting websites
96.
Compositions and methods for delivering cannabinoids to skin
Provided herein are compositions for delivering one or more cannabinoids to the skin of a subject and methods of using the compositions to deliver the one or more cannabinoids to the skin of a subject. The compositions contain a carrier that facilitates the delivery and permeation of cannabinoids to and through the skin. The carriers of the compositions contain squalane or mixtures of squalane and hemisqualane. The compositions described herein may serve as the base for the preparation of various cosmetics or various pharmaceuticals. The cosmetics or pharmaceuticals may be used to reduce inflammation, control pain, or prevent aging of the skin of a subject.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing synthetic biology laboratory services, namely, performing genomic modifications and installing and optimizing biosynthetic pathways in host cells to create, validate, scale-up and commercialize biotechnology products using tools for strain engineering, high throughput screening, analytics, bioinformatics, and process development
98.
COMPOSITIONS AND METHODS FOR DELIVERING CANNABINOIDS TO SKIN
Provided herein are compositions for delivering one or more cannabinoids to the skin of a subject and methods of using the compositions to deliver the one or more cannabinoids to the skin of a subject. The compositions contain a carrier that facilitates the delivery and permeation of cannabinoids to and through the skin. The carriers of the compositions contain squalane or mixtures of squalane and hemisqualane. The compositions described herein may serve as the base for the preparation of various cosmetics or various pharmaceuticals. The cosmetics or pharmaceuticals may be used to reduce inflammation, control pain, or prevent aging of the skin of a subject.
Provided herein antiperspirant composition formulations that contain hemisqualane and lack organosilicon compounds. The hemisqualane provides the carrier and emollient activities that are typically supplied by an organosilicon compound. The antiperspirant formulations provided herein have a benefit of not releasing organosilicon compounds into the environment during and after their use.
Provided herein are compositions for delivering one or more cannabinoids to the skin of a subject and methods of using the compositions to deliver the one or more cannabinoids to the skin of a subject. The compositions contain a carrier that facilitates the delivery and permeation of cannabinoids to and through the skin. The carriers of the compositions contain squalane or mixtures of squalane and hemisqualane. The compositions described herein may serve as the base for the preparation of various cosmetics or various pharmaceuticals. The cosmetics or pharmaceuticals may be used to reduce inflammation, control pain, or prevent aging of the skin of a subject.
